Copyright
©The Author(s) 2024.
World J Hepatol. Sep 27, 2024; 16(9): 1211-1228
Published online Sep 27, 2024. doi: 10.4254/wjh.v16.i9.1211
Published online Sep 27, 2024. doi: 10.4254/wjh.v16.i9.1211
Disease | Protein | Gene name and alias symbols | Role in liver disease | Vesicle source | Expression in disease |
NAFLD | Apolipoprotein C-III | Apolipoprotein C3 | An increased expression leads to increased steatosis in NAFLD[53] | EVs from human serum[53] | ↑ NAFLD patients[53] |
Composition: 79 AA | APOC3 | ||||
MW: 10.85 kDa | Apo-CIII | ||||
UA: P02656 | ApoC-III | ||||
HGNC ID: 610 | APOCIII | ||||
Cytogenetic band: 11q23.3 | Apo-C3 | ||||
ApoC-3 | |||||
Apolipoprotein C-I | Apolipoprotein C1 | An increased expression leads to increased steatosis in NAFLD[53] | EVs from human serum[53] | ↑ NAFLD patients[53] | |
Composition: 83 AA | APOC1 | ||||
MW: 9.33 kDa | |||||
UA: P02654 | |||||
HGNC ID: 607 | |||||
Cytogenetic band: 19q13.32 | |||||
Retinol-binding protein 4 | Retinol binding | Enhances the M1-like polarization of Kupffer cells via promoting the activation of NOX2 and NF-κB and ROS accumulation[72] | Serum exosomes from NAFLD patients[72] | ↑ NAFLD patients[72] | |
Composition: 201 AA | protein 4 | ||||
MW: 23.01 kDa | |||||
UA: P02753 | RBP4b | ||||
HGNC ID: 9922 | |||||
Cytogenetic band: 10q23.33 | |||||
Receptor-type tyrosine-protein phosphatase gamma | Protein tyrosine phosphatase receptor type G | Hepatic PTPRG mRNA increase proportionally to the severity of NAFLD[55] | Exosomes from human plasma and murine plasma, serum, and tissue[73] | ↑ of plasmatic approximately 120 kDa protein isoform were associated with the occurrence of liver damage[73] | |
↑ NASH[55] | |||||
Composition: 1445 AA | PTPRG | ||||
MW: 162.03 kDa | RPTPG | ||||
UA: P23470 | |||||
HGNC ID: 9671 | |||||
Cytogenetic band: 3p14.2 | |||||
C-X-C motif chemokine 10 | C-X-C motif chemokine ligand 10 | Lipotoxic hepatocyte-derived EVs containing CXCL10 induce macrophage chemotaxis[74,75] | EVs from Mlk3-/- mice[74,75] | ↑ NASH model[74,75] | |
Composition: 98 AA | |||||
MW: 10.88 kDa | CXCL10 | ||||
UA: P02778 | IFI10 | ||||
HGNC ID: 10637 | IP-10 | ||||
Cytogenetic band: 4q21.1 | crg-2 | ||||
mob-1 | |||||
C7 | |||||
gIP-10 | |||||
Fibulin-1 | Fibulin-1 | Correlate with fibrosis stage[54] | EVs from human serum[54] | ↑ NAFLD patients[54] | |
Composition: 703 AA | |||||
MW: 77,214 kDa | FBLN1 | ||||
UA: P23142 | FBLN | ||||
HGNC ID: 3600 | |||||
Cytogenetic band: 22q13.31 | |||||
Fibulin-3 | EGF containing fibulin extracellular matrix protein 1 | Increase with liver fibrosis. Predictor of liver-related events[54] | EVs from human serum[54] | ↑ NAFLD patients[54] | |
Composition: 493 AA | |||||
MW: 54.64 | EFEMP1 | ||||
UA: Q12805 | S1-5 | ||||
HGNC ID: 3218 | FBLN3 | ||||
Cytogenetic band: 2p16.1 | MTLV | ||||
NASH | Antithrombin-III | Serpin family C member 1 | Almost all of the downregulated proteins are produced in the liver[57] | Exosomes from HCC human serum samples[57] | ↑ ATIII in liver cirrhosis and HCC[57] |
Composition: 464 AA | |||||
MW: 52.6 kDa | SERPINC1 | ||||
UA: P01008 | ATIII | ||||
HGNC ID: 775 | MGC22579 | ||||
Cytogenetic band: 1q25.1 | |||||
Von Willebrand factor | Von Willebrand factor | Biomarker of severe liver fibrosis diagnosis and HCC development predictor[76] | Exosomal, from serum samples[57] | ↑ HCC[57] | |
Composition: 2813 AA | |||||
MW: 309.26 kDa | VWF | ||||
UA: P04275 | |||||
HGNC ID: 12726 | |||||
Cytogenetic band: 12p13.31 | |||||
Hemopexin | Hemopexin | ↓ HPX protein develops inflammation and oxidative stress in the liver[77] | Exosomal, from serum samples[57] | ↓ HCC[57] | |
Composition: 462 AA | |||||
MW: 51.67 kDa | HPX | ||||
UA: P02790 | |||||
HGNC ID: 5171 | |||||
Cytogenetic band: 11p15.4 | |||||
Galectin 3 binding protein | Galectin 3 binding protein | Significant biomarker in liver fibrosis, cirrhosis, and HCC in patients with hepatitis C[78] | Exosomes from serum samples[57] | ↑ HCC[57] | |
Composition: 585 AA | |||||
MW: 65.33 kDa. | LGALS3BP | ||||
UA: Q08380 | MAC-2-BP | ||||
HGNC ID: 6564 | 90K | ||||
Cytogenetic band: 17q25 | BTBD17B | ||||
ANGO10B | |||||
M2BP | |||||
gp90 | |||||
CyCAP | |||||
Cirrhosis | Transforming growth factor beta 1 | Transforming growth factor beta 1 | Promotes HSC activation and ECM production, contributing NAFLD progression[79,80] | Exosomal, from serum samples[57] | ↑ HCC[57] |
Composition: 390 AA | Hepatoma cell lines, culture media[81] | ↑ Promote tumor metastasis[81] | |||
MW: 44.32 kDa | TGFB1 | Ascites derived exosomes, from hepatic cirrhosis patients[82] | ↑ Promote cancer[82] | ||
UA: P01137 | CED | ||||
HGNC ID: 11766 | TGFbeta | ||||
Cytogenetic band: 19q13.2 | |||||
Fibulin-4 | EGF containing fibulin extracellular matrix protein 2 | Increased levels in cirrhosis, correlated with progression of fibrosis[56] | EVs from serum samples of patients with cirrhosis[56] | ↑ Cirrhosis[56] | |
Composition: 443 AA | |||||
MW: 49.4 kDa | EFEMP2 | ||||
UA: O95967 | |||||
HGNC ID: 3219 | |||||
Cytogenetic band: 11q13.1 | |||||
HCC | Haptoglobin | Haptoglobin | Patients with NAFLD with the Hp2-2 genotype had higher BMI, total cholesterol, and ferritin[83] | Exosomal, from serum samples[57] | ↓ HCC[57] |
Composition: 406AA | |||||
MW: 45.20 kDa | HP | ||||
UA: P00738 | |||||
HGNC ID: 5141 | |||||
Cytogenetic band: 16q22.2 | |||||
Hemoglobin subunit alpha | Hemoglobin subunit alpha 1 | Hemoglobin overexpression suppresses oxidative stress[57,84] | Exosomal, from serum samples[57] | ↓ HCC[57] | |
Composition: 142 AA | Liver biopsies from NASH patients[84] | ↑ NASH[84] | |||
MW: 15.258 kDa | HBA1 | ||||
UA: P69905 | HBA-T3 | ||||
HGNC ID: 4823 | |||||
Cytogenetic band: 16p13.3 | |||||
Fibrinogen alpha chain | Fibrinogen alpha chain | α chain fragments rapid alteration in early stages in liver fibrosis[85,86] | Exosomal, from serum samples[57] | ↓ HCC[57] | |
Composition: 866 AA, | |||||
MW: 94.97 kDa | FGA | ||||
UA: P02671 | |||||
HGNC ID: 3661 | |||||
Cytogenetic band: 4q31.3 | |||||
Fibrinogen gamma chain | Fibrinogen gamma chain | Rare cases of hypofibrinogenemia are associated with liver disease[87] | Exosomal, from serum samples[57] | ↓ HCC[57] | |
Composition: 453 AA | |||||
MW: 51.51 kDa | FGG | ||||
UA: P02679 | |||||
HGNC ID: 3694 | |||||
Cytogenetic band: 4q32.1 | |||||
Fibrinogen beta chain | Fibrinogen beta chain | Rarely, hypofibrinogenemia can present with HFSD[88] | Exosomal, from serum samples[57] | ↓ HCC[57] | |
Composition: 491 AA | |||||
MW: 55.928 kDa | FGB | ||||
UA: P02675 | |||||
HGNC ID: 3662 | |||||
Cytogenetic band: 4q31.3 | |||||
Carboxypeptidase E | Carboxypeptidase E | Promotes tumor metastasis and predicts tumor recurrence in early-stage HCC[58] | Exosomes from supernatant culture and human serum[57] | ↑ HCC Promote tumor metastasis[57] | |
Composition: 476 AA | |||||
MW: 53.15 kDa | CPE | ||||
UA: P16870 | |||||
HGNC ID: 2303 | |||||
Cytogenetic band: 4q32.3 | |||||
Vesicle-associated membrane protein-associated protein A | VAMP associated protein A | Facilitates bone-tropic metastasis of HCC by promoting osteoclastogenesis[41] | Large oncosomes from liver cancer mouse model[41] | ↑ HCC[41] | |
Composition: 249 AA | |||||
MW: 27.89 kDa | VAPA | ||||
UA: Q9P0L0 | hVAP-33 | ||||
HGNC ID: 12648 | VAP-A | ||||
Cytogenetic band: 18p11.22 | |||||
Basigin | Basigin (Ok blood group) | Induces angiogenesis by stimulating VEGF production and invasiveness by stimulating MMPs | Microvesicles from SMMC-7721 cell line (Hepatocellular carcinoma)[89] | ↑ HCC in vitro model[89] | |
Composition: 385 AA | BSG | Promotes the invasion and metastasis of human hepatoma cells by stimulating both tumor cells and peritumoral fibroblasts to produce elevated levels of MMPs[89] | |||
MW: 42.2 kDa | EMMPRIN | ||||
UA: P35613 | CD147 | ||||
HGNC ID: 1116 | EMPRIN | ||||
Cytogenetic band: 19p13.3 |
- Citation: Montoya-Buelna M, Ramirez-Lopez IG, San Juan-Garcia CA, Garcia-Regalado JJ, Millan-Sanchez MS, de la Cruz-Mosso U, Haramati J, Pereira-Suarez AL, Macias-Barragan J. Contribution of extracellular vesicles to steatosis-related liver disease and their therapeutic potential. World J Hepatol 2024; 16(9): 1211-1228
- URL: https://www.wjgnet.com/1948-5182/full/v16/i9/1211.htm
- DOI: https://dx.doi.org/10.4254/wjh.v16.i9.1211